Sarepta Therapeutics Approves Amendments at Annual Meeting

Sarepta Therapeutics ( (SRPT) ) has provided an announcement.

On June 5, 2025, Sarepta Therapeutics held its annual meeting where stockholders approved amendments to the company’s equity and employee stock purchase plans, increasing the number of shares available under these plans. Additionally, stockholders elected new directors, approved executive compensation, and ratified KPMG as the independent auditor, indicating strong shareholder support for the company’s strategic initiatives and governance.

The most recent analyst rating on (SRPT) stock is a Buy with a $200.00 price target. To see the full list of analyst forecasts on Sarepta Therapeutics stock, see the SRPT Stock Forecast page.

Spark’s Take on SRPT Stock

According to Spark, TipRanks’ AI Analyst, SRPT is a Neutral.

The overall score reflects significant financial health challenges, with strong revenue growth offset by negative profitability and cash flow issues. Technical analysis signals bearish momentum, and the stock’s valuation indicates potential overvaluation. Despite a positive demand outlook, short-term challenges remain due to safety incidents and administrative delays.

To see Spark’s full report on SRPT stock, click here.

More about Sarepta Therapeutics

Sarepta Therapeutics, Inc. operates in the biotechnology industry, primarily focusing on the development of precision genetic medicines to treat rare diseases. The company is known for its work in RNA-targeted therapeutics, gene therapy, and gene editing, with a significant emphasis on Duchenne muscular dystrophy and other neuromuscular diseases.

Average Trading Volume: 3,638,988

Technical Sentiment Signal: Sell

Current Market Cap: $3.89B

See more data about SRPT stock on TipRanks’ Stock Analysis page.